Immunomedics (NASDAQ: IMMU) is one of 190 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its competitors? We will compare Immunomedics to related businesses based on the strength of its analyst recommendations, earnings, valuation, profitability, institutional ownership, risk and dividends.
This table compares Immunomedics and its competitors’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Volatility and Risk
Immunomedics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Comparatively, Immunomedics’ competitors have a beta of 1.47, suggesting that their average stock price is 47% more volatile than the S&P 500.
Earnings & Valuation
This table compares Immunomedics and its competitors revenue, earnings per share and valuation.
Immunomedics’ competitors have higher revenue and earnings than Immunomedics. Immunomedics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
75.2% of Immunomedics shares are held by institutional investors. Comparatively, 48.8% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 6.6% of Immunomedics shares are held by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of recent recommendations for Immunomedics and its competitors, as reported by MarketBeat.
||Strong Buy Ratings
Immunomedics currently has a consensus target price of $21.00, indicating a potential upside of 25.97%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 12.83%. Given Immunomedics’ stronger consensus rating and higher probable upside, analysts plainly believe Immunomedics is more favorable than its competitors.
Immunomedics beats its competitors on 7 of the 13 factors compared.
Immunomedics Company Profile
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.